In Heilman and Valenstein's 1 widely used text, Clinical Neuropsychology, standing alone among the chapters dedicated to neurobehavioral syndromes (aphasia, agnosia, apraxia) is one entitled "The frontal lobes." This label subsumes executive cognitive functions, comportment, and the control and execution of motor activity, which includes both somatomotor and oculomotor systems. The oculomotor control system for saccades mediates reflexive responses influenced by the superior colliculus and volitional movements controlled by the frontal eye fields (FEF).
In Heilman and Valenstein's 1 widely used text, Clinical Neuropsychology, standing alone among the chapters dedicated to neurobehavioral syndromes (aphasia, agnosia, apraxia) is one entitled "The frontal lobes." This label subsumes executive cognitive functions, comportment, and the control and execution of motor activity, which includes both somatomotor and oculomotor systems. The oculomotor control system for saccades mediates reflexive responses influenced by the superior colliculus and volitional movements controlled by the frontal eye fields (FEF). 2 As initially reported over 30 years ago, the antisaccade task assesses a central feature of executive control, the ability to inhibit an automatic or prepotent response to a novel visual stimulus. 3 Test performance involves 2 separate tasks: 1) suppressing a reflex prosaccade toward a novel visual stimulus presented on one side, and 2) diverting gaze in the opposite direction by executing a volitional antisaccade. 4 A number of variations of this basic paradigm have been developed to evaluate neuropsychological processes such as visual attention, spatial memory, working memory, motivation, and decision-making across a variety of neurologic and psychiatric disorders. 5 In this issue of Neurology ® , 2 articles explore the common theme of saccadic eye-movement abnormalities in frontotemporal degeneration (FTD), but with different foci and aims. Burrell and colleagues 6 examine a theoretical model of decision-making speed, comparing individuals with FTD to normal controls. Across 2 experimental conditions, subjects with FTD showed increased mean saccade latency relative to controls, but similar saccade velocity. A third experimental condition used a binary choicereaction paradigm, with instructions to allow a reflex saccade toward a peripheral stimulus in one condition, or to inhibit that response and execute an antisaccade in the other condition. The complexity of this task, as reflected by the relative ratio of correct responses in controls compared to subjects with FTD (67% vs 57%), may limit interpretation despite a statistical difference between groups. Further, the FTD sample, consisting of 10 subjects with behavioral variant (bv) FTD and 12 subjects with primary progressive aphasia (PPA), showed marked subgroup differences, with the bvFTD subgroup accounting for most of the difference between FTD and control groups in mean saccade velocity and antisaccade performance. However, the occurrence of early saccades, a putative measure of executive dysfunction, was much higher in subjects with PPA compared to subjects with bvFTD. This measure and a derived measure for decision-making speed were independently correlated with atrophy in left anterior prefrontal regions approximating the FEF as measured by voxelbased morphometry. Previous studies using fMRI have implicated the FEF in triggering intentional saccades, with dorsolateral prefrontal cortex playing a greater role inhibiting reflex saccades. 7, 2, 4 Together, the 3 saccadic eye-movement experiments reported by Burrell et al. highlight FTD as a model disorder for investigating high-level executive functions, at least with these measures, but also illustrate limitations imposed by clinical heterogeneity in FTD.
Hellmuth et al. 8 report a 3-prong validation study of a clinical version of the antisaccade task as a measure of executive cognitive function. A criterion validation study of the standard bedside antisaccade (BAS) task, which involves displaying target stimuli on a laptop screen and having the examiner rate eyemovement direction, showed a strong correlation (r ϭ 0.86) with performance on a laboratory-based version of the antisaccade task using an infrared eye tracker. Although the BAS obviates the need for sophisticated eye-tracking equipment, it is dependent on examiner ratings of eye movements, which was not formally evaluated with interrater reliability testing. Among the 103 subjects tested on the BAS, most were either controls or subjects with frontotemporal lobar degeneration (FTLD), with small samples of subjects with Alzheimer disease (AD), mild cognitive impairment (MCI), and progressive supranuclear palsy (PSP). Raw performance on the BAS was virtually identical in subjects with AD and FTLD (57% and 58%, respectively), both being worse than controls (92%) and subjects with MCI (85%). However, subjects with PSP performed much worse than other groups, showing a mean correct response rate of only 35%. Although vertical gaze paresis is a hallmark feature of PSP, horizontal eye movements may also be compromised, which may have contributed to their poor performance on the BAS.
A second component of BAS validation compared performance on this measure to standard tests of executive function and tests representing other neuropsychological domains. Overall, BAS performance was selectively correlated with executive cognitive task performance, seen most robustly with modified Trails and design fluency, the only 2 graphomotordependent executive tests included in the battery. These findings suggest the need for further studies of BAS performance that control for potentially confounding elementary somatomotor and oculomotor dysfunction.
A third, and perhaps most fertile aspect of the BAS validation study, was a comparison of BAS performance to other measures of executive function that comprise a novel experimental test battery, Executive Abilities: Methods and Instruments for Neurobehavioral Evaluation and Research (EXAMINER). The BAS is part of this battery, which includes a mix of cognitive tests (e.g., Stroop interference, verbal fluency, N-back) and several social and behavioral informant-based ratings. As part of a multicenter validation study of the EXAMINER in almost 400 subjects ranging from 18 to 91 years of age and representing a variety of neurologic disorders, BAS performance correlated with most other EXAMINER tests. The Examiner measure most strongly correlated with BAS performance was the Frontal Systems Behavior Scale (FrSBe), an informant-based measure of frontal lobe behavioral syndromes (apathy, disinhibition, dysexecutive). 9 Although these data suggest that the BAS may broadly reflect clinical features associated with frontal lobe dysfunction, the strength of this association was relatively modest (r Ͻ 0.4).
The 2 current studies extend the antisaccade task both as a laboratory paradigm for investigating executive control and inhibitory processes and as an evaluative clinical research tool, using FTD as a model disorder. Burrell and colleagues employed variations of the antisaccade task in an elegant study of decision-making variables, which also identified performance differences among FTD subgroups that warrant further exploration. Hellmuth and colleagues report a translational research study validating a portable version of the antisaccade task (BAS), which together with other components of EXAMINER offer the prospect of a robust and comprehensive assessment for FTD and related disorders for multicenter clinical trials.
Supporting this application, executive cognitive impairment is strongly linked to functional disability, emphasizing its importance as a clinical outcome measure, and antisaccade task performance has been shown to be sensitive to pharmacologic manipulation. 10, 11 Both studies highlight use of the antisaccade task as a platform for cognitive neuroscience research, whether in a laboratory or clinical research venue.
A complex problem cutting across both studies is clinical heterogeneity of FTD. 12 The clinical spectrum of FTD includes bvFTD and PPA, which is subdivided into progressive nonfluent aphasia and semantic dementia subtypes. Across all 3 cognitivebehavioral phenotypes, many will also develop either parkinsonian motor features or clinical/subclinical features of motor neuron disease. Further work with BAS or similar tests may help classify subjects with FTD by a combination of distinctive executive cognitive and oculomotor features. Beyond this, multidimensional phenotypic profiling may help address the most vexing problem in FTD therapeutics-how to identify and distinguish among the different protein pathologies associated with FTD, including tau, TDP-43, and several other less common forms, using a combination of clinical and laboratory markers. 
